Recruiting Pulmonary Embolism Studies in Roma
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894)....
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis....
About Pulmonary Embolism Clinical Trials in Roma
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 2 pulmonary embolism clinical trials recruiting participants in Roma, . These studies are seeking a combined 178 participants. Research is being sponsored by Crinetics Pharmaceuticals Inc., Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in Roma — FAQ
Are there pulmonary embolism clinical trials in Roma?
Yes, there are 2 pulmonary embolism clinical trials currently recruiting in Roma, . Browse the studies on this page to find one that fits.
How do I join a clinical trial in Roma?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Roma research site will contact you about next steps.
Are clinical trials in Roma free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Roma studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 2 active trials in Roma are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov